ca88

¿ËÈÕ
£¬ÔÚ¹ú¼ÒÎÀ½¡Î¯ÁÙ¼ìÖÐÐÄ£¨National Center for Clinical Laboratories
£¬NCCL£©×éÖ¯µÄÒ©Îï´úлºÍÈéÏÙ°©HER2À©ÔöÊÒ¼äÖÊÆÀÖÐ
£¬ca88»ùÒòҽѧĥÁ·Ëù¶ÔÖ¤ÆÀÑù±¾µÄ¼ì²âЧ¹ûÓë¹Ù·½±ê׼Ч¹ûÍêÈ«Ò»ÖÂ
£¬ÒÔ5ÏîÈ«Âú·ÖµÄÓÅÒìЧ¹û˳Ëìͨ¹ýÁË´Ë´ÎÊÒ¼äÖÊÆÀ¡£

±¾´Îca88»ùÒò¼ÓÈëµÄÊÒ¼äÖÊÆÀÏîÄ¿°üÀ¨»ª·¨ÁÖÒ©Îï´úл»ùÒò£¨CYP2C9ºÍVKORC1£©¶à̬ÐÔ¡¢ÂÈßÁ¸ñÀ×Ò©Îï´úл»ùÒò£¨CYP2C19£©¶à̬ÐÔ¡¢Ò¶Ëá´úл»ùÒò£¨MTHFR£©¶à̬ÐÔ¡¢ÒÁÁ¢Ì濵ҩÎï´úл»ùÒò£¨UGT1A1£©¶à̬ÐÔ¡¢ÈéÏÙ°©HER2À©ÔöFISH¼ì²âµÈ5Ïî
£¬Ïêϸ¸÷ÏîÊÒ¼äÖÊÆÀЧ¹ûÏêϸÈçÏ£º

1.»ª·¨ÁÖÒ©Îï´úл»ùÒò£¨CYP2C9ºÍVKORC1£©¶à̬ÐÔ

2.ÂÈßÁ¸ñÀ×Ò©Îï´úл»ùÒò£¨CYP2C19£©¶à̬ÐÔ

3.Ò¶Ëá´úл»ùÒò£¨MTHFR£©¶à̬ÐÔ

4.ÒÁÁ¢Ì濵ҩÎï´úл»ùÒò£¨UGT1A1£©¶à̬ÐÔ

5.ÈéÏÙ°©HER2À©ÔöFISH¼ì²â

2020Äê×¢¶¨ÊÇÇ·ºàË×µÄÒ»Äê
£¬¸÷Ðи÷Òµ¶¼ÃæÁÙ×ÅÑÏËàµÄÌôÕ½¡£ca88»ùÒòʼÖÕ±ü³Ö“ÖÊÁ¿ÎªÆóÒµ×î»ù´¡µÄÉúÃüÁ¦”
£¬ÈÏÕæÓ­½Óÿһ´ÎÉóºË
£¬ÑϽ÷¼ì²âÿһ·ÝÑù±¾
£¬ÈÈÐÄÕÛÎñÿһλ¿Í»§¡£ÃæÁÙÌôÕ½
£¬Î¨ÓмáÊسõÐÄ
£¬Ó­ÄѶøÉÏ
£¬·½ÄÜÈñÒâ½øÈ¡
£¬È¡µÃÍ»ÆÆÐԵijɼ¨¡£Ôڴ˴εÄNCCLÊÒ¼äÖÊÆÀÖÐ
£¬ca88»ùÒòÒ»Èç¼ÈÍùµØÈ¡µÃÁËÓÅÒìµÄЧ¹û
£¬ÓÖÒ»´Î֤ʵÁËca88»ùÒòʵÑéÊÒÍêÉƵÄÖÎÀíÖƶȡ¢ÑÏ¿áµÄÖÊÁ¿¼à¿Øϵͳ
£¬×ÖÕå¾ä×õÄЧÀÍÀíÄî¡£ca88»ùÒò½«¼ÌÐøÑÏ¿á×ñÊØÐÐÒµ±ê×¼
£¬ÒÔ¸ßÖÊÁ¿µÄ¼ì²âЧÀ͸¨ÖúÁÙ´²Ò½ÉúΪ»¼ÕßÖƶ©¸öÌ廯µÄ¾«×¼ÓÃÒ©¼Æ»®
£¬Èÿí´ó»¼ÕßÔÚÁÆЧºÍ¾­¼Ã·½Ãæ»ñµÃ×î´óÊÜÒæ¡£

֪ʶÁ´½Ó

01.»ª·¨ÁÖÓëCYP2C9¡¢VKORC1

»ª·¨ÁÖÊÇÏÖÔÚÁÙ´²Ó¦ÓýÏΪÆÕ±éµÄÏ㶹ËØÀà¿Ú·þ¿¹ÄýÒ©Îï
£¬Ö÷ÒªÓÃÓÚÔ¤·ÀºÍÖÎÁÆѪ˨˨ÈûÐÔ¼²²¡
£¬ÆäÖÎÁÆ´°Õ­¡¢¸öÌå²î±ð´ó
£¬Ðèƾ֤¹ú¼Ê±ê×¼»¯±ÈÖµ(INR)µÄ¼à²âÖµÒ»Ö±µ÷½â¼ÁÁ¿¡£»ª·¨ÁֵIJ»Á¼·´Ó¦Ö÷Òª±¬·¢ÔÚ¸øÒ©³õÆÚ
£¬Òò¶ø׼ȷµØÕ¹Íû»ª·¨Áֵijõʼ¸øÒ©¼ÁÁ¿ºÍïÔÌ­»ª·¨ÁÖ¿¹Äý³õÆڵļÁÁ¿²¨¶¯ÊÇ»ª·¨ÁÖ¸öÌ廯ÖÎÁÆÈ·µ±ÎñÖ®¼±¡£½üÄêÀ´µÄÑо¿Åú×¢
£¬´úлϸ°ûÉ«ËØP450ø2C9(CYP2C9)ºÍ°ÐµãÂÑ°×άÉúËØK»·Ñõ»¯Îﻹԭø¸´ºÏÌåÑǵ¥Î»1(VKORCl)»ùÒò¶à̬ÐÔÊÇÓ°Ï컪·¨ÁÖʹÓüÁÁ¿µÄÖ÷ÒªÒÅ´«ÒòËØ¡£

»ª·¨ÁÖÔÚÌåÄÚ85%ÒÔÉÏÊÇÓɸÎҩøCYP2C9´úлת»¯ÎªÎÞ»îÐÔµÄÒ©Îï¡£×÷Ϊϸ°ûÉ«ËØÑõ»¯Ã¸P450³¬¼Ò×åÖеijÉÔ±
£¬CYP2C9¾ßÓи߶ȶà̬ÐÔ
£¬±£´æ¶àÖÖ¼î»ùÍ»±ä
£¬CYP2C9µÄ»ùÒòÑÇÐÍÓÐ*£±¡¢*£²¡¢*£³
£¬ÆäÖÐ*£±ÎªÒ°ÉúÐÍ
£¬*£²ºÍ*£³ÎªÍ»±äÐÍ¡£ÌåÍâºÍÌåÄÚÑо¿Åú×¢
£¬CYP2C9*2ºÍ*3½µµÍ»ª·¨ÁֵĴúлÂÊ»®·ÖΪ30-40%ºÍ80-90%¡£ÓëCYP2C9*1´¿ºÏ×Ó»¼ÕßÏà±È
£¬ÒÅ´«Ò»¸ö»òÁ½¸öCYP2C9*2»ò*3µÄ¸öÌåÔÚ»ª·¨ÁÖÖÎÁÆʱ´úÓиü´óµÄ³öѪΣº¦
£¬ÐèÒª¸üµÍµÄ¼ÁÁ¿À´µÖ´ïÏàËƵĿ¹Äýˮƽ
£¬²¢ÇÒÐèÒª¸ü¶àµÄʱ¼äÀ´µÖ´ïÎȹ̵ÄINR¡£

×÷ΪάÉúËØKÑ­»·ÖеÄÒªº¦Ã¸
£¬VKORClλÓÚ16ºÅȾɫÌå¶Ì±Û£¨16P11.2£©ÉÏ
£¬±àÂëÇøºÍ·Ç±àÂëÇø±£´æ×Å´ó×Ú¶à̬ÐÔλµã
£¬³£¼ûµÄ·Ç±àÂë±äÌåVKORC1
£¬c.-1639G>A£¨rs9923231£©
£¬Ó뻪·¨ÁÖµÄÃô¸ÐÐÔÔöÌíºÍʹÓüÁÁ¿ïÔÌ­ÓйØ¡£ÓëGAºÍGGÐÍ»¼ÕßÏà±È
£¬VKORCl-1639AAÐÍ»¼ÕßʹÓûª·¨ÁÖµÄƽ¾ù¼ÁÁ¿ÏÔ×ÅïÔÌ­¡£ÆäÔ­ÓÉÓÚ
£¬GAºÍGGÐÍÆô¶¯Òò×Ó»îÐԽϸß
£¬µ¼ÖÂmRNA±í´ïÔöÌí¡¢VKORCl»îÐÔÉý¸ß¡£

02.ÂÈßÁ¸ñÀ×ÓëCYP2C19

ÂÈßÁ¸ñÀ×ÊÇÒ»ÖÖ¿¹ÑªÐ¡°åÒ©Îï
£¬ ÆÕ±éÓÃÓÚ¼±ÐÔ¹ÚÂö×ÛºÏÕ÷¡¢ ȱѪÐÔÄÔѪ˨¡¢ ±ÕÈûÐÔÂö¹ÜÑ׺Ͷ¯ÂöÓ²»¯¼°ÑªË¨Ë¨ÈûÒýÆðµÄ²¢·¢Ö¢¡£ÂÈßÁ¸ñÀ×ÊÇÒ»ÖÖÇ°ÌåÒ©Îï
£¬ Ö»ÓÐͨ¹ý»úÌå´úл²Å»á±¬·¢¾ßÓлîÐԵĿ¹ÑªÐ¡°å´úл²úÆ·
£¬¶øλÓÚ¸ÎÔàÖеÄCYP2C19øÔÚÆä´úлÀú³ÌÖÐÆðÖ÷Òª×÷Óá£

CYP2C19µÄ²î±ð»ùÒòÐÍÓ°ÏìÆä±àÂëøµÄ»îÐÔ¼°ÂÈßÁ¸ñÀ׵ĴúлËÙÂÊ
£¬½ø¶øÓ°ÏìÁÆЧ¼°¸±×÷Óá£ÂÈßÁ¸ñÀ׵ķ´Ó¦ÐÔ»áÔÚCYP2C19*£²*£³µÈλ»ùÒòЯ´øÕßÖз´Ó¦ÐÔ½µµÍ
£¬·ºÆðÂÈßÁ¸ñÀ׶Կ¹
£¬È±ÑªÐÔ²»Á¼ÐÄѪ¹ÜÊÂÎñ±¬·¢ÂÊÒ»Ö±ÌáÉý
£¬¶øЯ´øCYP2C19*£²»¼Õß¾­¶þÁ×ËáÏÙÜÕ£¨ADP£©ÓÕµ¼ÑªÐ¡°åȺ¼¯ÂÊÏÔןßÓÚÆäËû»¼Õß
£¬¾ßÓÐÂÈßÁ¸ñÀ׵ͷ´Ó¦ÐÔ¡£±ðµÄ
£¬ÂÈßÁ¸ñÀ×µÄѪС°åÒÖÖÆ×÷ÓÿÉͨ¹ýCYP2C19*17ÔöÇ¿
£¬¼´CYP2C19*17Я´øÕ߶ÔÂÈßÁ¸ñÀ×¾ßÓнÏÇ¿·´Ó¦ÐÔ¡£

ÁÙ´²Ò©Îï»ùÒò×éѧʵÑéͬÃË(CPIC)ÒÑÐû²¼ CYP2C19 »ùÒò¼ì²âºÍÂÈßÁ¸ñÀ׸öÌ廯ÖÎÁƵÄÖ¸ÄÏ
£¬ÓÃÓÚÖ¸µ¼ÄÇЩÒÑÖªCYP2C19»ùÒòÐÍ»òÕßÁÙ´²Ò½Ê¦Ñ¡ÕªÒª×ö CYP2C19»ùÒò·ÖÐ͵Ļ¼Õ߸öÌ廯ÓÃÒ©¡£Òò´Ë
£¬ÂÈßÁ¸ñÀ×Ò©Îï´úл»ùÒò£¨CYP2C19£©¶à̬ÐÔ¼ì²âÊÇʵÏÖÂÈßÁ¸ñÀ׸öÌ廯¾«×¼ÓÃÒ©µÄÖ÷ÒªÊֶΡ£

03.Ò¶ËáÓëMTHFR

Ò¶ËáÊÇ»úÌåϸ°ûÉú³¤ºÍ×ÌÉú±Ø²»¿ÉÉÙµÄÒ»ÖÖB×åάÉúËØ
£¬È±·¦Ò¶ËáÓëÉñ¾­¹Ü»ûÐΡ¢¾ÞÓ×ϸ°ûѪÐé¡¢´½ëñÁÑ¡¢ÒÖÓôÖ¢¡¢Ö×ÁöµÈ¼²²¡ÓÐÖ±½Ó¹Øϵ¡£Ò¶Ëá²»µ«ÊDZ¸ÔкÍÔгõÆڵij£ÓÃÒ©
£¬Ò²ÊÇHÐ͸ßѪѹ»¼ÕßÐèÒªÔö²¹µÄÒ©Îï
£¬ÒԴ˽µµÍѪҺÖеÄͬÐÍ°ëë×°±Ëáˮƽ
£¬×èÖ¹ÒòѪÖеÄͬÐÍ°ëë×°±ËáŨ¶È¹ý¸ß
£¬Òý·¢¶¯ÂöÖàÑùÓ²»¯ºÍ¹ÚÐIJ¡µÈ¸ßѪѹµÄÑÏÖز¢·¢Ö¢¡£

MTHFR»ùÒòC677T¡¢A1298CλµãÊÇÒ¶Ëá´úлͨ·Ïà¹Ø»ùÒò³£¼ûµÄµ¥ºËÜÕËá¶à̬λµã
£¬ËüÃǶÔÒ¶Ëá´úлҪº¦Ã¸µÄ»îÐÔÓ°ÏìºÜ´ó
£¬¿ÉÒÔµ¼ÖÂÒ¶Ëá´úлÕÏ°­
£¬ÑªÒºÖÐͬÐÍ°ëë×°±ËáˮƽÉý¸ß
£¬ÓëÐÂÉú¶ù³öÉúȱÏÝ¡¢²»Ôв»Óý¡¢ÐÄÄÔѪ¹Ü¼²²¡¡¢°©Ö¢µÈ¶àÖÖ¼²²¡·¢²¡Î£º¦µÄÌá¸ßÇ×½üÏà¹Ø¡£¼ì²âMTHFR»ùÒò¶à̬ÐÔ
£¬Ã÷È·¸öÌåµÄÒ¶Ëá´úлÄÜÁ¦
£¬¿ÉÒÔÖ¸µ¼Ò¶ËáµÄ¸öÐÔ»¯Ôö²¹
£¬ÓÐÀûÓÚÔ¤·ÀÐÄÄÔѪ¹Ü¼²²¡µÄ±¬·¢ºÍÉú³¤
£¬ÓÐÀûÓÚ½µµÍ³öÉúȱÏÝÂÊ¡£

04.ÒÁÁ¢Ì濵ÓëUGT1A1

ÒÁÁ¢Ì濵£¨Irinotecan£©ÊÇÍØÆËÒ칹ø¢ñÒÖÖƼÁ
£¬¿ÉÌØÒìÐÔµØ×÷ÓÃÓÚϸ°ûÖÜÆÚSÆÚ
£¬Ê¹DNAºÏ³ÉÊÜ×è´Ó¶ø±¬·¢Ï¸°û¶¾ÐÔ×÷ÓÃ
£¬ÊÇÁÙ´²ÉÏÖ÷ÒªµÄÖ×Áö»¯ÁÆÒ©Îï
£¬ÔÚ½áÖ±³¦°©¡¢Î¸°©¡¢·Î°©¡¢ÒÈÏÙ°©µÈʵÌåÖ×ÁöµÄÖÎÁÆÖоùÌåÏÖ³ö½ÏºÃµÄЧ¹û¡£µ«ÒÁÁ¢Ì濵ÊÇÒ»ÖÖÇ°ÌåÒ©Îï
£¬½øÈëÈËÌåºóÐèÒªÌØÊâµÄ´úл;¾¶²Å»ªÌìÉúÑÄÐÔ´úл²úÆ·¡£Õâ¸öÀú³ÌÐèÒªÌض¨Ã¸¼ÓÈë´ß»¯
£¬UGT1A1ÊÇÒÁÁ¢Ì濵´úлÀú³ÌµÄÒªº¦Ã¸
£¬¿É½«Æä»îÐÔ´úл²úÆ·SN-38ÆÏÌÑÌÇÈ©ËữΪÎÞ»îÐÔµÄSN-38G
£¬ºóÕßÓɵ¨Ö­Éø͸½øÈ볦µÀ
£¬×îÖÕËæÄòÒºÇãÔþÌåÍâ¡£

SN-38»îÐÔ½ÏÒÁÁ¢Ì濵ǿ100¡«1000±¶
£¬Ï¸°û¶¾ÐÔԼΪÒÁÁ¢Ì濵µÄ200¡«2000±¶£»Í¬Ê±
£¬ÓÐÑо¿Ö¸³ö
£¬ÒÁÁ¢Ì濵»¯ÁÆÏà¹Ø²»Á¼·´Ó¦Ö÷ÒªÓëSN-38µÄÐî»ýÓйØ¡£UGT1A1*6 ºÍ UGT1A1*28µÄÍ»±ä¾ù»áʹ UGT1A1ø»îÐÔ½µµÍ
£¬Ôì³ÉSN-38µÄÐî»ý
£¬´Ó¶øÒý·¢Ïà¹Ø²»Á¼·´Ó¦£¨È縹к¼°ÖÐÐÔÁ£Ï¸°ûïÔÌ­µÈ£©¡£±ðµÄ
£¬UGT1A1*6ºÍUGT1A1*28»ùÒò¶à̬ÐÔÓ뺬ÒÁÁ¢Ì濵¼Æ»®»¯ÁƵÄÁÆЧҲÓйØ¡£ÓëÒ°ÉúÐÍ»¼Õß½ÏÁ¿
£¬UGT1A1*28Í»±äÐÍ»¼ÕߵĿ͹ۻº½âÂÊ£¨ORR£©¿ÉÔöÌí20%
£¬UGT1A1*6ºÍ/»òUGT1A1*28»ùÒòÍ»±äÐÍ»¼Õß¾ßÓиü³¤µÄÖÐλϣÍûʱ¼äºÍ×ÜÉúÑÄÆÚ¡£

Òò´Ë
£¬ÔÚÑ¡ÔñÒÁÁ¢Ì濵»¯ÁÆÇ°¾ÙÐÐUGT1A1»ùÒò¶à̬ÐÔ¼ì²â
£¬¿Éƾ֤¸öÌå²î±ðÃ÷È·¸øÒ©¼ÁÁ¿
£¬×èÖ¹ÒÁÁ¢Ì濵µÄ¼ÁÁ¿ÏÞÖÆÐÔ¶¾ÐÔ
£¬Ìá¸ßÁÆЧ
£¬¼õÇỼÕߵĻ¯ÁÆÍ´¿à
£¬ÔöÇ¿ÒÀ´ÓÐÔ¡£

05.ÈéÏÙ°©HER2À©ÔöÓëFISH¼ì²â

HER2ÊÇÒ»ÖÖÔ­°©»ùÒò
£¬ÔÚÕý³£µÄÈéÏÙ×éÖ¯ÖÐ
£¬HER2¼ÓÈëϸ°ûÉú³¤·¢ÓýµÄÐźÅתµ¼Àú³Ì£»ÔÚÈéÏÙ°©»¼ÕßµÄÖ×Áöϸ°ûÖÐ
£¬Ò»µ©HER2»ùÒò·ºÆðÀ©Ôö
£¬½«»á¼ÓËÙÖ×ÁöµÄÐγɺÍÔöÌí
£¬²¢´Ì¼¤°©Ï¸°û±¬·¢Ô¶´¦×ªÒÆ¡£

HER2»ùÒòÊÇ·ñÀ©Ôö
£¬²»µ«ÊÇÈéÏÙ°©»¼ÕßµÄÇ¿Ô¤ºó±ê¼Ç
£¬Ò²Ö±½ÓÓ°Ïì×ÅÁÙ´²ÖÎÁƼƻ®µÄÑ¡Ôñ¡£ÈéÏÙ°©±ê±¾Ò»Ñùƽ³£¿ÉÏÈ×öÃâÒß×éÖ¯»¯Ñ§£¨IHC£©¼ì²â¡£IHC 3+ÅжÏΪHER2ÑôÐÔ
£¬IHC 0ºÍ1+ÔòÅжÏΪHER2ÒõÐÔ¡£IHC 2+ÕßÐè½øÒ»²½Ó¦ÓÃԭλÔÓ½»µÄÒªÁì¾ÙÐÐHER2»ùÒòÀ©Ôö״̬¼ì²â
£¬µ¥¿½±´HER2»ùÒò>6»òHER2/CEP17±ÈÖµ>2.0
£¬±»ÅжÏΪHER2ÑôÐÔ¡£HER2ÑôÐÔÓëÒõÐÔ»¼ÕßµÄÁÙ´²ÖÎÁƼƻ®ÍêÈ«²î±ð
£¬HER2ÒõÐÔ»¼Õß
£¬²»ÍƼöHER2°ÐÏòÖÎÁÆ£»¶øÇúÍ×Öéµ¥¿¹¡¢ÅÁÍ×Öéµ¥¿¹µÈ°ÐÏòÒ©ÔòÊÇÈéÏÙ°©HER2ÑôÐÔ»¼ÕßÊõÇ°¡¢ÊõºóµÄÒ»ÏßÖÎÁÆÕ½ÂÔ¡£

ÔÚÈéÏÙ°©HER2À©ÔöµÄ¼ì²âÒªÁìÉÏ
£¬Öظ´ÐÔºÍÒ»ÖÂÐÔ¸üºÃµÄÓ«¹âԭλÔÓ½»£¨fluorescence in situ hybridization
£¬FISH£©¼ì²â±»ÒÔΪÊÇHER2¼ì²âµÄ “½ð±ê×¼”¡£Óɴ˿ɼû
£¬ÈéÏÙ°©HER2À©ÔöFISH¼ì²âÔÚÈéÏÙ°©»¼ÕßµÄÕïÖη¾¶Öбز»¿ÉÉÙ
£¬ÓëÈéÏÙ°©µÄÕïÁÆЧ¹ûÇ×½üÏà¹Ø¡£

²Î¿¼×ÊÁÏ:
[1]Vestergaard A S , Skjth F , Larsen T B , et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis[J]. PLoS ONE, 2017, 12(11):e0188482.
[2]Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404.
[3]Scott S A , Sangkuhl K , Stein C M , et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.[J]. Clinical Pharmacology & Therapeutics, 2013, 94(3):317-323.
[4]ºÎÕðÓî.Ò¶Ëá´úлͨ·³£¼û»ùÒò¶à̬λµã¼°Æä¼ì²âÒªÁì[J].¹ã¶«Ò©¿Æ´óѧѧ±¨,2020,36(3):440-445.
[5]Paulík, Adam, Nekvindová, Jana, Filip S . Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine[J]. Tumori, 2018.
[6]Paulík A, Grim J, Filip S. Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer.[J]. Acta Medica, 2012, 55(4):153-9.
[7]Xing-Han L , Jun L , Wei D , et al. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy[J]. Journal of Cancer, 2017, 8(4):691-703.
[8]Takahara N , Nakai Y , Hiroyuki Isayama…. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.[J]. Cancer Chemotherapy & Pharmacology, 2013, 71(1):85-92.
[9] Bari?M, Kuli?A, Sirotkovi?-SkerlevM, et al. Circulating HER2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, HER2/neu receptor coexpression[J]. Pathol Oncol Res, 2015, 21(3): 589-595. DOI: 10.1007/s12253-014-9859-6.
[10] ÈéÏÙ°©ÕïÁƹ淶(2018Äê°æ)[J].Ö×Áö×ÛºÏÖÎÁƵç×ÓÔÓÖ¾,2019,5(3):70-99.
[11]¡¶ÈéÏÙ°©HER2¼ì²âÖ¸ÄÏ(2019°æ)¡·±àд×é.ÈéÏÙ°©HER2¼ì²âÖ¸ÄÏ(2019°æ)[J].Öлª²¡ÀíѧÔÓÖ¾,2019,48(3):169-175.